GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...